Fisetin as a Senolytic Therapy - Quick Reference Sheet
evipedia.ai ← Back

Fisetin as a Senolytic Therapy

Created on 07/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Fisetin is a common plant pigment studied for clearing worn-out "zombie" cells that build up with age. In aging mice it improved blood-vessel health, strength, bone, and lifespan. Human studies are small, short, and reassuring on safety but unproven for benefit. Poor absorption limits it. Promising but early. (Full Review)

Protocol

Dose
~20 mg/kg/day
Research protocol; supplement use often fixed 100–1500 mg
Schedule
2–3 days per cycle
Intermittent "hit-and-run" dosing, repeated after weeks (e.g., monthly)
Administration
With fat-containing meal
Daily amount often split across the day to improve tolerability and absorption
Time to effect
Felt Effect
None immediate
No immediate felt effect; works by clearing senescent cells over cycles
Benefit
Weeks to months
Emerges slowly over repeated dosing; largely measured by biomarkers
Washout
Weeks to months
After stopping, senescent cells gradually reaccumulate over weeks to months toward the pre-treatment state

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Active cancer under treatment
  • Narrow-therapeutic-index medications without medical oversight
  • Significant liver impairment (e.g., Child-Pugh Class C)
    •
Key Interactions
  • Narrow-therapeutic-index agents (warfarin, some chemotherapeutics, certain immunosuppressants such as cyclosporine)
  • NSAIDs (ibuprofen, naproxen, aspirin)
  • Other senolytics and flavonoids (quercetin, dasatinib, curcumin, resveratrol)
  • Blood-pressure-lowering or blood-thinning supplements (fish oil, garlic extract, nattokinase, magnesium, quercetin)
  • Chemotherapy, radiation, or surgery
    •

Risk & Side Effects

  • High:
  • Medium: Limited long-term human safety data
    •
  • Low: Gastrointestinal effects; blood pressure lowering; potential drug-metabolism interference
    •
  • Speculative: Theoretical genotoxicity/mutagenicity signal; impaired tissue repair from over-clearance of senescent cells
    •

Monitoring

Marker Target Why
hs-CRP < 1.0 mg/L Tracks systemic inflammation that senescent cells drive
IL-6 Low-normal per lab A senescence-associated secretory factor; proposed target of senolytic effect
ALT / AST ALT < 25 U/L (F) / < 30 U/L (M) Detects any liver stress given hepatic metabolism of fisetin
eGFR > 90 mL/min/1.73m² Confirms kidney function before/during use
Blood pressure ~110–120 / 70–80 mmHg Captures fisetin's mild blood-pressure-lowering effect
Fasting glucose / HbA1c Glucose 70–85 mg/dL; HbA1c < 5.4% Screens metabolic effects suggested in preclinical work

Cadence: Baseline before first cycle, safety recheck after the first 1–2 cycles, then every 6–12 months if cycling continues; blood pressure around dosing days.

Qualitative Assessment

  • Energy and vitality: subjective sense of energy and reduced fatigue across dosing cycles
  • Physical function: ease of walking, grip and general strength, recovery from exertion
  • Joint comfort: stiffness and joint pain
  • Cognitive clarity: subjective focus and mental sharpness
  • Overall resilience: recovery from minor illness or physical stress
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.